Why Aptose Biosciences (APTO) Stock Is Down Over 40%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 01 2025
0mins
Source: Benzinga
Aptose Biosciences Delisting: Aptose Biosciences Inc. announced it will be delisting from the Nasdaq due to its inability to meet equity requirements by the March 31 deadline, resulting in a 43.4% drop in share price to $1.78.
Continued Trading on TSX: Despite the delisting from Nasdaq, Aptose's shares will continue to be traded on the Toronto Stock Exchange as the company focuses on developing a new drug therapy for acute myeloid leukemia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
